Mark J O'Connor

Title: Mark J O'Connor: Innovator in Cancer Treatment Detection

Introduction

Mark J O'Connor is a notable inventor based in Little Chesterford, GB. He has made significant contributions to the field of oncology through his innovative methods for detecting RAD51 foci in tumor cells. His work aims to improve the treatment outcomes for cancer patients by determining their sensitivity or resistance to anti-cancer therapies.

Latest Patents

Mark J O'Connor holds a patent for a method that allows for the determination of whether a subject diagnosed with cancer is sensitive or resistant to anti-cancer treatment. This method is based on the level of cells with RAD51 foci in a sample containing tumor cells isolated from the subject. The invention specifies that the subject must not have received certain chemotherapy treatments within 24 hours prior to sample isolation, and the sample must not be treated with methods that induce DNA damage before the analysis.

Career Highlights

Throughout his career, Mark has worked with prominent organizations, including the Fundació Privada Institut D'Investigació Oncològica de Vall Hebron and AstraZeneca UK Limited. His experience in these institutions has allowed him to contribute to groundbreaking research in cancer treatment.

Collaborations

Mark has collaborated with esteemed colleagues such as Violeta Serra Elizalde and Judith Balmaña Gelpi. These partnerships have further enriched his research and development efforts in the field of oncology.

Conclusion

Mark J O'Connor's innovative work in cancer treatment detection exemplifies the impact of dedicated inventors in the medical field. His contributions continue to pave the way for advancements in patient care and treatment efficacy.